Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01261325 · ClinicalTrials.gov registry record · Phase 3
Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 768
- Enrollment target
NCT01261325 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 768 participants.
The verdict
NCT01261325, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 768 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.
Interventions
- DRUG Placebo
- DRUG Brivaracetam
- DRUG Antiepileptic drugs with market authorization available per country
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 768 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01261325
The ClinicalTrials.gov registry entry for NCT01261325 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 768 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01261325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01261325 about?
NCT01261325 is a clinical study titled "Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures". This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.
What is the current status of trial NCT01261325?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 768 participants. The study started on 2010-12. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01261325?
The interventions under investigation include: Placebo (DRUG), Brivaracetam (DRUG), Antiepileptic drugs with market authorization available per country (DRUG).
Who is sponsoring clinical trial NCT01261325?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.